Clinical trials: Neoplasms, Solid Tumor
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
This trial is an open-label, multicenter, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT05153096
- Testing
- NBL-015
- Where
- China
- Volunteers
- 410 people
- Sponsor
- NovaRock Biotherapeutics, Ltd
Cancer, Tumor, Solid
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies.
- Conditions
- Cancer, Tumor, Solid, Refractory Cancer
- Trial name
- NCT04640246
- Testing
- TBX-3400
- Where
- 2 sites in United States, Israel
- Volunteers
- 60 people
- Sponsor
- Taiga Biotechnologies, Inc.
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
This is the first-in-human study with SYD1875, an antibody-drug conjugate (ADC) comprising of a humanized IgG1 monoclonal antibody directed against the 5T4 oncofetal antigen covalently conjugated to a duocarmycin-based…
- Trial name
- NCT04202705
- Testing
- SYD1875
- Where
- 3 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
This phase I trial studies the side effects and best dose of adavosertib when given together with olaparib in treating patients with solid tumors that have spread to other places in the body (advanced) with selected mutations.
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04197713
- Testing
- Adavosertib, Olaparib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules…
- Trial name
- NCT03059823
- Testing
- retifanlimab
- Where
- 80 sites in United States, Australia and 14 more
- Volunteers
- 325 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
- Trial name
- NCT01928459
- Testing
- BGJ398, BYL719
- Where
- 22 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
- Trial name
- NCT06446388
- Testing
- QLS31905, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasm Malignant
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR566658 Secondary Objectives: To characterize the safety profile of SAR566658 To evaluate the pharmacokinetic profile of SAR566658 To assess the potential…
- Trial name
- NCT01156870
- Testing
- SAR566658
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Sanofi
Advanced Solid Tumours, Small Cell Lung Cancer
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy…
- Trial name
- NCT04434482
- Testing
- IMP4297(senaparib)
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 59 people
- Sponsor
- Impact Therapeutics, Inc.
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Cancer, Critical Illness
Cancer Patients Treated With Immunotherapy in Intensive Care Unit
This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.
- Conditions
- Cancer, Critical Illness, Immunotherapy
- Trial name
- IMMUNO-REA (NCT03357861)
- Where
- 2 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
Ewing's Sarcoma
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
Primary Objectives: 1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. 2.
- Trial name
- NCT00492141
- Testing
- Temozolomide, L9-NC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
- Trial name
- NCT06703177
- Testing
- SHR-1826, SHR-4642, SHR-9839
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Recurrent Solid Tumor
Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma
With open, single/ multiple dosing and dose escalation, phase I clinical trial scheme to evaluate safety, tolerance and pharmacokinetic properties of Genolimzumab injection in Chinese patients of advanced and (or) recurrent solid…
- Conditions
- Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
- Trial name
- GB226 (NCT03374007)
- Testing
- Geptanolimab Injection 1mg/kg, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Genor Biopharma Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05757492
- Testing
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Coherus Oncology, Inc.
Chronic Myeloproliferative Disorders, Leukemia
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424 in…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT01164163
- Testing
- ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
- Where
- 24 sites in United States
- Volunteers
- 49 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Solid Cancer Metastatic Disease, Lymphoid Disease
Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency
Anemia in patients with cancer is a common problem associated with an impaired quality of life. Treatment with erythropoiesis stimulating agents (ESA) allows an increase in hemoglobin levels in 40-70% of patients and decreased…
- Trial name
- NCT02213653
- Testing
- ARM A : IV iron + epoietin zeta, ARM B: IV iron + epoietin zeta sequence, ARM C : single epoietin zeta
- Where
- 2 sites in France
- Volunteers
- 24 people
- Sponsor
- Centre Francois Baclesse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.